Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”

Clarification on the news article by Commercial Times
September 20, 2018
Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study
September 28, 2018
  1. Date of occurrence of the event: Sept 20, 2018
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
  4. Reciprocal shareholding ratios: N/A
  5. Name of mass media: Commercial Times
  6. Content reported: “…Biotech industry is profitable. OBI received Orphan Drug Designation…”
  7. Cause of occurrence: Clarification on news article
  8. Countermeasures: OBI-3424 was granted FDA Orphan Drug Designation for the treatment of Acute Lymphoblastic Leukemia (abbreviated as ALL). Please refer to MOPS announcement on Sept 19, 2018.
  9. Any other matters that need to be specified: new drug development is a long process associated with high costs. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.